Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Cylex, Inc. Appoints Brad L. Stewart As Chief Executive Officer and Chairman of the Board
StockPreacher.Com Issues Trading Outlook for Keryx Biopharmaceuticals Inc.
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
Amicus Therapeutics Announces First Quarter 2009 Financial Results
Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Amicus Therapeutics Announces Change to Board of Directors
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Amicus Therapeutics to Present at J.P. Morgan Healthcare Conference
Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Amicus Therapeutics Opens Research Facility in San Diego
Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
Amicus Therapeutics Announces First Quarter 2008 Financial Results - Jun 3 2008 3:16AM
Amicus Therapeutics Announces First Quarter 2008 Results Release Date - Jun 3 2008 3:14AM
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
